Showing results (1-10 of 213) with videos related to
Sort By:
Pageof 22
Health Economics|December 19, 2006
Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVAAnthony O'Hagan, Matt Stevenson, Jason MadanValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 3, 2009
A rapid-response economic evaluation of the UK NHS Cancer Reform Strategy breast cancer screening program extension via a plausible bounds approachJason Madan, Andrew Rawdin, Matt Stevenson, et al.Pharmaceutical Statistics|April 3, 2009
The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulationRichard M Nixon, Anthony O'Hagan, Jeremy Oakley, et al.Pharmacoeconomics|December 16, 2010
Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisalMatt Stevenson, Abdullah PandorJournal of Health Economics|May 4, 2004
On estimators of medical costs with censored dataAnthony O'Hagan, John W StevensInternational Journal of Technology Assessment in Health Care|February 27, 2003
Incorporation of genuine prior information in cost-effectiveness analysis of clinical trial dataJohn W Stevens, Anthony O'HaganHealth Economics|December 17, 2002
Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?Anthony O'Hagan, John W StevensPsychometrika|March 28, 2015
Advances in Modeling Model Discrepancy: Comment on Wu and Browne (2015)Robert C MacCallum, Anthony O'HaganBMC Medical Research Methodology|March 27, 2002
The probability of cost-effectivenessAnthony O'Hagan, John W StevensInternational Journal of Technology Assessment in Health Care|April 11, 2008
Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursementChristopher McCabe, Karl Claxton, Anthony O'HaganPageof 22